Get the Stockscreener App
7.73
9.67%
-0.80
Biohaven Ltd stock is traded at $7.73, with a volume of 2.78M.
It is down -9.67% in the last 24 hours and down -48.70% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$8.53
Open:
$8.35
24h Volume:
2.78M
Relative Volume:
0.96
Market Cap:
$818.82M
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.0091
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
-55.20%
1M Performance:
-48.70%
6M Performance:
-59.49%
1Y Performance:
-85.49%
1-Day Range:
$7.63
$8.38
1-Week Range:
$7.63
$16.45
52-Week Range:
$7.63
$54.53
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
7.74 | 902.40M | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.86 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
646.25 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.73 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.21 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Can Biohaven Ltd. stock resist sector downturnsJuly 2025 Update & Daily Entry Point Alerts - newser.com
Will Biohaven Ltd. stock remain a Wall Street favoriteBull Run & Risk Controlled Swing Trade Alerts - newser.com
Why hedge funds are buying Biohaven Ltd. stockJuly 2025 Update & AI Optimized Trading Strategy Guides - newser.com
Earnings visualization tools for Biohaven Ltd.July 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes - TipRanks
Biohaven: CRL Setback For SCA But Degrader Platform Advancement Warrants 'Hold' Rating - Seeking Alpha
Biohaven price target lowered to $30 from $75 at Piper Sandler - TipRanks
Biohaven (BHVN): Bernstein Downgrades and Lowers Price Target | - GuruFocus
Deutsche Bank Adjusts Biohaven Price Target to $15 From $29, Maintains Buy Rating - MarketScreener
Biohaven price target lowered to $16 from $33 at BTIG - TipRanks
Market reaction to Biohaven Ltd.’s recent newsShort Setup & Real-Time Market Trend Scan - newser.com
Why Biohaven Ltd. stock is favored by pension funds2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
How Biohaven Ltd. stock benefits from global expansionWeekly Trading Summary & AI Enhanced Trading Signals - newser.com
BTIG Maintains Biohaven (BHVN) Buy Recommendation - Nasdaq
Is a relief rally coming for Biohaven Ltd. holdersEarnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
Will Biohaven Ltd. stock reach Wall Street targets2025 Technical Overview & Stepwise Swing Trade Plans - newser.com
Will Biohaven Ltd. stock maintain momentum in 20252025 Fundamental Recap & Consistent Profit Alerts - newser.com
Biohaven downgraded to Market Perform from Outperform at Bernstein - TipRanks
Biohaven (BHVN): Assessing Valuation After FDA Rejects VYGLXIA and Strategic Restructuring - simplywall.st
Is Biohaven Ltd. stock a buy for dividend growthEarnings Risk Report & Weekly Top Stock Performers List - newser.com
Biohaven tanks as FDA issues CRL for Vyglxia - The Pharma Letter
What Fibonacci levels say about Biohaven Ltd. reboundPortfolio Growth Summary & Weekly Chart Analysis and Trade Guides - newser.com
Why retail investors pile into Biohaven Ltd. stockWeekly Profit Summary & Daily Momentum Trading Reports - fcp.pa.gov.br
Bernstein downgrades Biohaven stock to Market Perform on liquidity concerns - Investing.com India
How cyclical is Biohaven Ltd. Common Shares stock compared to rivalsJuly 2025 Levels & Risk Adjusted Swing Trade Ideas - newser.com
Can Biohaven Ltd. stock maintain growth trajectoryWall Street Watch & Momentum Based Trading Signals - fcp.pa.gov.br
Biohaven Shares Plunge As FDA Rejects Key Brain Drug - Finimize
Will Biohaven Ltd. stock gain from strong economyCEO Change & Long-Term Safe Investment Plans - newser.com
Signal strength of Biohaven Ltd. stock in tech scanners2025 Market Outlook & Long Hold Capital Preservation Tips - newser.com
Vanguard Group Inc. Reduces Stake in Biohaven Ltd - GuruFocus
How Biohaven Ltd. stock compares to growth peers2025 EndofYear Setup & Fast Gain Swing Alerts - fcp.pa.gov.br
Biohaven stock plummets as Leerink slashes price target on FDA concerns - Investing.com
Strategic Realignment and Pipeline Potential Drive Buy Rating for Biohaven Ltd. - TipRanks
Biohaven Resorts To Cost-Cutting After Troriluzole Hit With FDA CRL - Citeline News & Insights
Biohaven CRL leads to cutbacks and program reprioritization - BioWorld MedTech
Biohaven stock downgraded by BofA after FDA rejection of troriluzole - Investing.com
Biohaven downgraded to Neutral from Buy at BofA - TipRanks
Key facts: Biohaven shares drop 40% after FDA rejects Vyglxia; company cuts R&D costs by 60% - TradingView
BHVN: TD Cowen Lowers Price Target, Maintains Buy Rating | BHVN Stock News - GuruFocus
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Benzinga
Biohaven sinks as FDA rejects lead drug (update) (BHVN:NYSE) - Seeking Alpha
Knocked back by the FDA, Biohaven turns to major cost cuts - BioPharma Dive
Crude Oil Down 1%; Solid Power Shares Spike Higher - Benzinga
Raymond James reiterates Strong Buy on Biohaven stock despite setbacks - Investing.com
Biohaven stock plummets after FDA issues Complete Response Letter By Investing.com - Investing.com Canada
Biohaven stock falls after FDA rejects troriluzole for SCA By Investing.com - Investing.com Australia
Biohaven (BHVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Biohaven Ltd.: Strategic Initiatives and Financial Positioning Drive Buy Rating Amid FDA Challenges - TipRanks
Dow Surges 100 Points; McDonald's Posts Downbeat Earnings - Benzinga
Biohaven Facing Challenges: Stock Outlook - StocksToTrade
Biohaven shares plunge after US FDA declines to approve brain disorder drug - Reuters
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):